Providing market intelligence for more than 35 years

In The News

mHealth Looks to Solve the Diabetes Care Management Conundrum

Earlier this year, a report from digital health analyst Parks Associates found that 27 percent of people with a chronic condition want a mobile health device that tracks their health, but a significant percentage of those now using such devices say they’re too complicated or don’t work well.

"Nearly one-half of type I diabetics and one-third of type II diabetics are interested in health monitoring devices such as glucometers, but a steep learning curve and difficult or counterintuitive directions could inhibit their usage of these devices and also prevent them from buying other connected health devices," Harry Wang, the group’s senior director of research, said in a press release accompanying the report. "Device and application manufacturers would benefit from improving the ease-of-use of these devices." 

From the article "mHealth Looks to Solve the Diabetes Care Management Conundrum" by Eric Wicklund.

Previously In The News

What Should Apple Name Its Next New iPhone?

Pew has also reported that 68% of smartphone owners use their phone to follow along with breaking news events at least occasionally, 67% use their phone for turn-by-turn navigation while driving, and...

Women Know What Consumers Want: VCs Need To Wise Up

A whopping 117 million Americans are expected to need assistance with caregiving, according The Caregiving Innovation Frontiers by AARP and Parks Associates. It’s a $42.9 billion market. Yet, perhaps...

WWE's Stephanie McMahon on the Power of Letting Fans Call the Shots

The company is a leader in the streaming market—it launched an OTT (over-the-top) Internet-based streaming service in 2014. According to research firm Parks Associates, the WWE’s service is the fifth...

Netflix Earnings Preview: Is Streaming Video Giant Still Snagging New Subscribers?

On top of that, the industry churn rate—a metric used to reflect cancelled subscriptions to streaming services overall—shot up 41% in Q1, the most recent statistic available, as consumers experimented...